Mortimer Ian, President & CEO of XENE Therapeutics (ticker: XENE), has demonstrated a clear selling bias in recent insider transactions, with no purchases recorded in the latest filings. Since December 2025, Ian has executed 15 sales totaling approximately $21.3 million against a lifetime buy total of just $2.3 million, with all activity concentrated in XENE shares. The most significant disposals occurred in a concentrated burst on March 9, 2026, when Ian sold $4.03 million, $3.70 million, and $2.57 million worth of shares alongside smaller transactions that day totaling an additional $6.1 million. This was followed by further sales of $677,357 on March 10 and $403,584 on March 13.
The transactions show a pattern of methodical divestment, with sales executed both as open-market disposals (code S) and through derivative transactions (code M). Notably, the March disposals coincided with the vesting of equity awards (code A filings with $0 value), suggesting routine sales of vested positions. Prior to this cluster, Ian had conducted smaller sales in December 2025 and January 2026, including a $1.68 million transaction on January 2. The absence of any buy transactions since at least December 2025 reinforces the directional trend toward reducing exposure to XENE equity.
AI-assisted summary